Lunai Bioworks (LNAI) Depreciation & Amortization (CF) (2013 - 2026)
Lunai Bioworks (LNAI) posted quarterly Depreciation & Amortization (CF) of $19634.0 for Q1 2026, down 38.6% year-over-year from $31975.0 in Q1 2025, and up 73.26% quarter-over-quarter from $11332.0 in Q4 2025.
Lunai Bioworks (LNAI) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Lunai Bioworks' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $19634.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 38.6% year-over-year to $19634.0; the TTM figure through Mar 2026 stood at $105114.0 (down 17.62% YoY), while the FY2025 annual figure was $129095.0, up 5.94% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $19634.0, up from $11332.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $41522.0 in Q3 2025, with the low at $11332.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $30305.0 (2024), against an average of $29234.7.
- Peak annual rise in Depreciation & Amortization (CF) reached 28.21% in 2025, while the deepest fall reached 64.71% in 2025.
- Lunai Bioworks' Depreciation & Amortization (CF) stood at $28844.0 in 2022, then increased by 14.97% to $33162.0 in 2023, then slipped by 3.18% to $32109.0 in 2024, then plunged by 64.71% to $11332.0 in 2025, then soared by 73.26% to $19634.0 in 2026.
- Business Quant data shows LNAI's Depreciation & Amortization (CF) at $19634.0 in Q1 2026, $11332.0 in Q4 2025, and $41522.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 19,634.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,634.00 |
| Mar 31, 2026 | 19,634.00 |
| Dec 31, 2025 | 11,332.00 |
| Dec 31, 2025 | 11,332.00 |
| Sep 30, 2025 | 41,522.00 |
| Sep 30, 2025 | 41,522.00 |
| Jun 30, 2025 | 32,626.00 |
| Jun 30, 2025 | 32,626.00 |
| Mar 31, 2025 | 31,975.00 |
| Mar 31, 2025 | 31,975.00 |
| Dec 31, 2024 | 32,109.00 |
| Dec 31, 2024 | 32,109.00 |
| Sep 30, 2024 | 32,385.00 |
| Sep 30, 2024 | 32,385.00 |
| Jun 30, 2024 | 31,132.00 |
| Jun 30, 2024 | 31,132.00 |
| Mar 31, 2024 | 30,305.00 |
| Mar 31, 2024 | 30,305.00 |
| Dec 31, 2023 | 33,162.00 |
| Dec 31, 2023 | 33,162.00 |